Hünerbein M
Department of Surgery and Surgical Oncology, Robert Rössle Hospital, Humboldt University of Berlin, Germany.
Recent Results Cancer Res. 1998;146:48-55. doi: 10.1007/978-3-642-71967-7_4.
Currently CEA is the most accurate tumor marker for colorectal cancer. Preoperative determination of this marker can assist staging, treatment planning and in particular postoperative follow-up of colorectal cancer. Postoperative CEA monitoring should be performed every 3 months. Further evaluation for local recurrence or metastatic disease is mandatory if elevated or increasing CEA levels occur after radical surgery. However, present data do not justify using CEA alone for postoperative follow-up and monitoring of adjuvant therapy. Molecular genetic techniques are now increasingly performed to detect genetic alterations that can be used as prognostic markers. In the future, identification and quantification of these genes may even be valuable in defining the susceptibility of healthy individuals for colorectal cancer.
目前，癌胚抗原（CEA）是结直肠癌最准确的肿瘤标志物。术前测定该标志物有助于结直肠癌的分期、治疗方案制定，尤其是术后随访。术后应每3个月进行一次CEA监测。如果根治性手术后CEA水平升高或持续上升，则必须进一步评估是否存在局部复发或转移性疾病。然而，目前的数据并不支持单独使用CEA进行术后随访和辅助治疗监测。现在越来越多地采用分子遗传学技术来检测可作为预后标志物的基因改变。未来，这些基因的鉴定和定量甚至可能有助于确定健康个体患结直肠癌的易感性。
